Welcome to Markets Desk, here's what's moving the needle right now.
Starbucks is pulling back its footprint, announcing the closure of roughly two hundred fifty underperforming North American locations as the company pushes to refocus on its core coffeehouse experience. Chief Operating Officer Mike Grams outlined the strategy in a memo to staff, framing the cuts as a return to fundamentals and a bid to drive customers back through the door.
Turning to healthcare, the debate over Bristol Myers Squibb versus Pfizer is sharpening heading into the back half of two thousand twenty six. Bristol Myers continues to generate strong free cash flow anchored by its oncology and neuroscience franchises, while Pfizer faces its own post-pandemic repositioning. Analysts are watching which name offers better risk-adjusted value at current levels.
And on the analyst wire, Jefferies has upgraded Nestlé's depositary receipt from Hold to Buy, a notable shift for the consumer staples giant. The move signals growing confidence in Nestlé's margin recovery and pricing power after a prolonged period of volume pressure across its global portfolio. It's the kind of upgrade that tends to draw institutional attention back to a name that had gone quiet.
That's the tape. Markets Desk, signing off the floor.
